Legend Biotech Corp Asset Resilience Ratio
Legend Biotech Corp asset resilience ratio. Legend Biotech Corp (LEGN) has an Asset Resilience Ratio of 16.66% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Legend Biotech Corp for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Legend Biotech Corp (2018–2025)
Asset resilience ratio of Legend Biotech Corp from 2018 to 2025. This chart shows how Legend Biotech Corp's Asset Resilience Ratio has changed over time. See LEGN free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Legend Biotech Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Legend Biotech Corp (LEGN) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $291.71 Million | 16.66% |
| Total Liquid Assets | $291.71 Million | 16.66% |
Asset Resilience Insights
- Good Liquidity Position: Legend Biotech Corp maintains a healthy 16.66% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Legend Biotech Corp Industry Peers by Asset Resilience Ratio
Compare Legend Biotech Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Legend Biotech Corp Asset Resilience Ratio by Year (2018–2025)
Legend Biotech Corp asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Legend Biotech Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.69% | $46.70 Million | $1.73 Billion | -47.36pp |
| 2024-12-31 | 50.05% | $835.93 Million | $1.67 Billion | +48.37pp |
| 2023-12-31 | 1.68% | $31.00 Million | $1.85 Billion | -16.33pp |
| 2022-12-31 | 18.00% | $239.62 Million | $1.33 Billion | +0.72pp |
| 2021-12-31 | 17.28% | $193.46 Million | $1.12 Billion | +10.36pp |
| 2020-12-31 | 6.92% | $50.00 Million | $722.09 Million | -19.34pp |
| 2019-12-31 | 26.26% | $75.56 Million | $287.71 Million | +24.86pp |
| 2018-12-31 | 1.40% | $6.01 Million | $429.05 Million | -- |
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more